INNOVATION: THE DRIVING FORCE FOR GROWTH

Company Presentation
“The choices made to allow PharmaNutra to grow and steadily evolve have brought us to celebrate 20 years in business. In this time, we have never lost sight of the values on which our company was built. PharmaNutra’s vision has always been to use scientific research and technology in the best possible way, to educate on wellness, prevention and health. The pride and satisfaction we feel when we think about PharmaNutra history, alongside the ambition and certainty accompanying each strategic choice, are our company’s best visiting card.
We really believe in the values PharmaNutra was founded on. We also believe that words such as ethics, responsibility, research, innovation and respect - what we cherish for those accompanying each step we take - have a true, profound, current meaning. Because how we do business is based on these concepts, as are the solid foundations on which we built a company now recognised as one of Italian excellence - with commitment, determination and a touch of healthy madness. Our words are always facts and we like being concrete. With no filters or compromise. We really believe in ourselves because we know we have revolutionised complex markets like the pharmaceutical and nutraceutical ones, with products made using innovative, patented technologies. A company looking to the future, strong with its ongoing, increasingly more intense Research & Development activities, continuously expanding abroad. One that can grow and establish itself, even in the sports world, through sponsorship of excellence. Well aware that any enterprise must be based on financial solidity. That’s us, PharmaNutra. And we are really proud of it.”

ANDREA AND ROBERTO LACORTE
Founders of PharmaNutra S.p.A.
Our Company in figures

- Market Cap*: +603% (vs. listing July 2017)
- Foreign sales partners: 45
- Present in countries worldwide: 67
- Patents: 21
- Proprietary raw materials: 45
- Registered trademarks: 40
- Proprietary research studies and clinical trials published: 158
- CAGR on consolidated turnover 2017-2021: +15.4%
- Market share of Sideral® in Italy (source: IQVIA): 55.3%
- Employees in Italy: 30
- Sports clubs supported through partnerships: 30

Data updated to 31/12/2022
# TABLE OF CONTENTS

<table>
<thead>
<tr>
<th>Section</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>WHO WE ARE</td>
<td>13</td>
</tr>
<tr>
<td>RESEARCH &amp; DEVELOPMENT</td>
<td>27</td>
</tr>
<tr>
<td>BUSINESS MODEL</td>
<td>39</td>
</tr>
<tr>
<td>COMMITMENT</td>
<td>51</td>
</tr>
</tbody>
</table>
**Manifesto**

**VISION**
Thinking outside the box leads to extraordinary results, with a bold approach and increasingly challenging goals.

**SPEED**
Keeping in step with change means being one step ahead, which translates into a competitive time-to-market and an accelerated global expansion strategy.

**SOLIDITY**
Growing is only possible if you have solid, concrete bases, in the company this means not only counting on results and financial soundness but also on the commitment of our people.

**INNOVATION**
Guaranteeing reliability and efficacy is the secret of success, our know-how comes from our continuous investments in R&D and the protection of our intellectual property.

**DETERMINATION**
This is not just a business attitude, but the forward-looking vision of a company, aiming towards continuous improvement.
WHO WE ARE
“The history of this company and its rapid growth has always been marked by waves of innovation. Like the tide: specific phases, marked by extraordinary events and amazing moments.”

ROBERTO LACORTE
CEO and co-founder of PharmaNutra S.p.A.

2000
ALESCO
Establishment of a new company specialised in nutraceutical raw materials.

2003
PHARMANUTRA
PharmaNutra is founded, for the development of medical devices and nutraceutical products.

2008
SIDERAL®
Launch of the company’s first proprietary brand on the market.

2010
NEW STRATEGIC PLAN
PharmaNutra opens to external investors to launch a new development plan.

2013
JUNIA PHARMA
Establishment of a new company focusing on the paediatric sector.

2014
INTERNATIONAL DISTRIBUTION
Signature of the first foreign distribution contract.

2016
ELITE
PharmaNutra enters the Borsa Italiana Elite programme to consolidate and accelerate its growth.

2017
AWARDS
The SiderAl® c.r.m. patent is voted “Readers Ingredient of the Year” by the scientific journal NutraIngredients.

2019
Euronext Growth Milan
The PharmaNutra Group is listed on the Euronext Growth Milan market of the Italian Stock Exchange.

2020
TOP SELLER
SiderAl® Forte 20 capsule is the best-selling nutritional supplement in Italy (Federaisus IQVIA data).

2022
AKERN
PharmaNutra started and completed the acquisition of 100% of the shares in Akern S.r.l.

2023
NEW STRATEGIES FOR GROWTH
Incorporation of PharmaNutra USA and PharmaNutra España.

NEW FACILITIES
Inauguration of the new PharmaNutra chemical-pharmaceutical cluster.
WHO WE ARE

YEARS ANNIVERSARY

Founded and managed by the Lacorte brothers, PharmaNutra S.p.A. was born in 2003 with the aim of developing nutritional supplements and innovative medical devices, overseeing the whole production process, from the development of proprietary raw materials to the distribution of the finished product. With its products distributed worldwide, in less than 20 years the company has succeeded in making its mark as a leading player in the iron-based oral nutritional supplements market, where it boasts major patents linked to Sucrosomial® Technology, and it is also considered to be one of the emerging top players in the sector of medical devices for the recovery of joint capacity.

PHARMANUTRA

In 2010 PharmaNutra's top management decided to invest in the creation of a new company, aiming to respond to the increasing health needs of children as a starting point for a healthier society. This led to the establishment of Junia Pharma S.r.l., the company specialised in the development and distribution of paediatric medicines, medical devices, OTC products and nutritional supplements. With its constant attention to the needs of the paediatric world and the quality and safety of its products, today Junia Pharma is present in Italy and in many foreign countries, acting as a point of reference for general practitioners and families.

JUNIA PHARMA

Alesco S.r.l. was established in 2000 to stand out on the nutraceutical market for the high scientific value of the raw materials distributed. Thanks to its ongoing R&D investments, company activities focussed on studying iron and minerals and implemented the Sucrosomial® Technology in 2010. In under ten years, that unique, innovative delivery system has revolutionised the martial therapies and mineral-based supplements sector. Alesco active principles are considered the most effective on the market and are used in the pharmaceutical, food and cosmetic sectors.

ALESCO

Akern S.r.l. was founded in 1980, dedicated to the research, development and production of medical instruments and software for monitoring body composition using bioimpedance techniques. The company mission is to support doctors and researchers in their challenge to fight chronic degenerative diseases, guaranteeing clinically significant results to support diagnosis and the choice of treatment. Over the years, Akern has developed technologies that have allowed the company to be recognised in Europe as a benchmark for body composition science. Akern joined the PharmaNutra Group in 2022.

AKERN

The PharmaNutra Group

“PharmaNutra was born from a dream: that of improving personal well-being starting from the properties of the micro- and macronutrients taken in through food. We have truly believed in this, we have taken risks, we have focused everything on our intuitions and our very own method. And we will continue to do so.”

ANDREA E ROBERTO LACORTE

Founders of PharmaNutra S.p.A.
Dear investor,

We are pleased to share with you the results of a journey that is leading us closer and closer to excellence. In the space of a decade, the Pharmanutra Group has grown significantly, earning a leadership position on the Italian iron-based food supplement market, and is progressively gaining shares in the topical products and immunostimulants market. This growth is accompanied by a progressive development in foreign markets.

All this is thanks to continuous innovation, reliability, motivated staff, financial soundness and investments.

The results achieved lay the foundations for the future development of the Group, in which the new headquarters play a fundamental role. The biomolecular research centre, one of the most pioneering in Europe, will reduce the development times for new raw materials and new products; the site where our proprietary raw materials will be produced will ensure more production flexibility for the Group; our employees will be able to work in a comfortable, safe environment with a range of services available to them. All with a view to sustainability.

We have created value, and will continue to do so, with drive, determination and plenty of enthusiasm.
The real challenge of modern medicine is to be able to intervene before people need it. How to make a difference? First of all, through curiosity. Only the curious study, listen, find things out and therefore know, and are able to understand the evolution of society, with a constant eye on the healthcare world. Education comes before prevention, passing obligatorily through knowledge.

We work to prevent people from getting sick. A project that goes beyond the concept of prevention, as it concerns nutritional culture and awareness.

We enhance natural elements with our technology, making nutritional supplements that are effective and with no contra-indications.

We know the human body, and we know that the first step to safeguarding health is to make its natural defences strong and effective.

“And when we started out, I had a very clear goal in mind: to put science safely and effectively at the service of nutrition. We created a market and introduced new nutritional concepts and new active ingredients, convinced that our technology is able to make a difference.”

ANDREA LACORTE
President and co-founder of PharmaNutra S.p.A.

◆ Cure by educating to well-being
We work to prevent people from getting sick. A project that goes beyond the concept of prevention, as it concerns nutritional culture and awareness.

◆ Cure by making people feel well
We enhance natural elements with our technology, making nutritional supplements that are effective and with no contra-indications.

◆ Cure by making people stronger
We know the human body, and we know that the first step to safeguarding health is to make its natural defences strong and effective.
We have always been committed to working according to the principles of transparency, innovation and continuous growth, in both scientific and human terms. The primary objective of the PharmaNutra management system is to create value using an ethical, responsible approach, without losing sight of the social relevance of our activities and stakeholders. This is why, every year, the Sustainability Report is our starting point for setting priorities and constantly evolving, with a view to sustainable development in the science and business world as well as in the local community where we operate.

The challenge for the future

“We desire to explain our activities in a Sustainability Report came about immediately after the first COVID-19 emergency, because we were convinced of the need to define new standards, new rules, new life styles starting precisely from our day-to-day business management”

ANDREA E ROBERTO LACORTE
Founders of PharmaNutra S.p.A.

OUR APPROACH TO SUSTAINABILITY
In line with its vision and mission, the PharmaNutra Group joined the 2030 Agenda for Sustainable Development (the ‘Agenda’), considering how the company can contribute to the Sustainable Development Goals (SDGs) in a more direct way. Below are the material issues identified by the PharmaNutra Group associated with the relevant SDGs, demonstrating the contribution that Group companies can make towards achieving the SDGs.

<table>
<thead>
<tr>
<th>Issue</th>
<th>SDG 3</th>
<th>SDG 4</th>
<th>SDG 5</th>
<th>SDG 8</th>
<th>SDG 9</th>
<th>SDG 10</th>
<th>SDG 11</th>
<th>SDG 12</th>
<th>SDG 13</th>
<th>SDG 14</th>
<th>SDG 15</th>
<th>SDG 16</th>
</tr>
</thead>
<tbody>
<tr>
<td>Waste Management and Recycling</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Energy Efficiency</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Corporate Welfare and Employee Career Development</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Health and safety in the Workplace</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Diversity and Equal Opportunities</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Responsible Procurement Management</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Product Quality and Safety</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cybersecurity and Data Responsibility</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Ethics Integrity and Anti-Corruption</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Sustainable Value Creation</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
What drives our growth

“Always look ahead, never settle for less, never stop celebrating achievements, and continue to throw yourself whole-heartedly into new challenges.”

ANDREA LACORTE
President and co-founder of PharmaNutra S.p.A.

This is the PharmaNutra spirit. A strong attitude more than a philosophy, which is reflected in and can be felt in all the company’s figures and fields. PharmaNutra’s growth path has always been - and will continue to be - based on three fundamental aspects: people, the defence of its intellectual property and determination.

Great businesses are great not only thanks to the efficacy of their products but above all for the value of the people who contribute to their development through their daily work and sacrifices. In an environment in which efficacy and innovation are the founding pillars of all activities, caring for people means paying attention to the dynamics of different working groups, but also demanding quality, professionalism and dedication. At PharmaNutra we believe in talent, but we believe even more in commitment and willpower, because the success of a business can be achieved only when it is able to guarantee a future, security, work and values for all its staff.

As a company working in the health and well-being sector, the quality of our products and company processes is an indispensable value, to which we pay particular attention through a structured system of Quality Control and Assurance that governs all our activities at every level. PharmaNutra S.p.A. is certified to SA 8000:2014 and UNI EN ISO 9001:2015.
RICERCA E SVILUPPO
"We began with an intuition: applying the knowledge acquired in food technologies to medicines. The further our scientific research progressed, the more our intuitions, supported by research and field work, became certainties. And today, those certainties are our patents.”

GERMANO TARANTINO
Chief Scientific Officer PharmaNutra S.p.A.

The R&D activities are the beating heart of PharmaNutra. The know-how acquired in years of scientific research, clinical trials and publications have allowed the Group’s companies to obtain 21 patents and control 20 raw materials within the whole value chain, held exclusively on both the Italian and foreign markets. A unique value and an essential strategic asset, as well as the foundations on which we continue to work to build a future where scientific progress is at the service of collective well-being, understood as prevention and attention to health.

THE GROUP’S R&D SYSTEM

- **Scientific rigour**
  The protection of our intellectual property, patents and raw materials is the key to our uniqueness.

- **Innovation**
  Cutting-edge research and clinical trials constantly guide us in the development of new products and solutions.

- **Rapid development**
  Flexible interdisciplinary resources drive our development in a constantly changing world.
Research and scientific cooperation

Scientific partnerships with top universities and academic institutes are a fundamental part of the company’s growth. On one hand, they have allowed PharmaNutra to become increasingly aware of the quality and importance of its research, acquiring skills through dialogue and exchange of knowledge with sector experts. On the other, cooperating actively with research centres outside the company represents an important recognition of the scientific value of the Group.

AMONG OUR KEY PUBLICATIONS:

Sucrosomial® Iron absorption studied by in vitro and ex-vivo models

Effects of different regimens of iron prophylaxis on maternal iron status and pregnancy outcome: a randomized control trial

Oral sucrosomial® Iron versus intravenous iron in anemic cancer patients without iron deficiency receiving darbepoetin alfa: a pilot study

Sucrosomial® Iron: A New Generation Iron for Improving Oral Supplementation
Gómez-Ramírez S., Brilli E., Tarantino G., Muñoz M., Pharmaceuticals. 2018

Safety and efficacy of sucrosomial® Iron in inflammatory bowel disease patients with Iron deficiency anemia

Improved patient blood management and cost saving in hip replacement surgery through the implementation of pre-operative Sucrosomial® Iron supplementation: a quality improvement assessment study
Scardino M., Di Matteo B., Martorelli F., Tanzi D., Kon E., D’Amato T., International Orthopaedics. 2018

CLINICAL RESEARCH

158 clinical trials in progress (the last year alone)
7k patients involved
48 full articles published in journals
24 ongoing clinical studies

BASIC RESEARCH

23 studies published on the role played by the raw materials developed by the PharmaNutra Group
4 complete studies on the kinetic mechanism of Sucrosomial® Iron
6 studies presented at international scientific congresses
Sucrosomial® Technology

“When scientific intuition meets courage and determination, great projects and great stories are born. But this only happens if we continue to invest in research to take our discoveries to the next step.”

ANDREA LACORTE
President and co-founder, PharmaNutra S.p.A.

Sucrosomial® Technology was developed to solve a concrete problem found in millions of people worldwide. Iron deficiency anaemia is the most common nutritional disease, and most existing martial therapies are highly limiting, on one hand due to the significant associated side-effects and on the other to the known difficulties the body has in absorbing iron.

In 2010 PharmaNutra deposited the Sucrosomial® Technology patent, a unique and innovative delivery system that, in less than a decade, has revolutionised the therapy sector and, generally, the mineral-based supplements market.

Is it possible to improve iron and minerals to make them more bioavailable and, above all, absorbable, without risks to health?

Food technologies were the inspiration and starting point: a phospholipid structure able to protect the element while also increasing its absorption. From here began the scientific procedure which, under the supervision of Dr. Andrea Lacorte and Dr. Germano Tarantino, led to the development of many in-vitro studies, clinical research, analyses, comparisons, publications, up to the definition of the first Sucrosomial® structure applied to iron.
Sucrosomial® Iron has been described as the most innovative oral iron in numerous consensus papers.

The Sideral® r.m. (Sucrosomial® Iron) patent underlying the nutritional supplements in the SiderAL® line, marks a significant turning point in the treatment of iron deficiency (sideropenia). The number of studies and publications in Italy and abroad confirming its validity and efficacy continues to increase. In 2016 Sideral® r.m. was voted “Readers Ingredient of the Year” by the famous, authoritative industry journal Nutraingredients.com. Its success in the medical and commercial field has allowed PharmaNutra to invest new resources to refine and further improve Sucrosomial® Technology, which today is successfully applied not only to iron but also to many other minerals that are essential for the human body: magnesium, zinc, selenium, iodine, calcium and chromium.

The Sucrosomial® Technology of the future...

PharmaNutra has already begun to develop second-generation Sucrosomes®, new and advanced delivery systems that are able to enhance an increasing number of elements. So not only minerals but also vitamins and phytoextracts, aiming to improve the tolerability, bioavailability and absorption of these nutrients, which in future will play an increasingly central role in the pharmaceutical, nutraceutical and food market.
The innovation of Cetylated Fatty Acids

“We have always worked in close contact with the sports world, we ourselves are sportsmen and Cetilar® was developed to offer an effective and practical response to problems we faced first-hand.”

ROBERTO LACORTE
CEO and co-founder, PharmaNutra S.p.A.

In recent years PharmaNutra has invested significantly in research to develop new formulations able to effectively respond to problems relating to the treatment of musculoskeletal conditions. The idea comes from our constant dialogue with many professionals in the sports and physiotherapy world, constantly looking for valid and easy-to-use natural products for motor recovery and muscle and joint well-being. In 2015 the company developed Cetilar® r.m., the innovative patent behind the products in the Cetilar® range, launched on the market in October 2016. In 2022, in addition to Cetilar® r.m. comes Lipocet®, a novel food made with cetylated esters of fatty acids created for the development of oral formulations for muscle and joint well-being.

Cetilar®, a natural aid for joint physiology
Cetilar® r.m. is a complex of highly concentrated Cetylated Fatty Acids (7.5% CFAs) that stabilise and lubricate the cell membranes to restore the joint liquid, ensuring normal flexibility and mobility of joints, muscles and tendons. The CFAs, obtained from the reaction of natural fatty acids with Cetyl Alcohol, rapidly and effectively pass through the skin barrier, which is normally impermeable to many of the active ingredients contained in the topical formulations available on the market today. This mechanism not only restores the functions of the damaged membrane, but also rapidly reduces joint and musculoskeletal pain.

Lipocet®, the evolution of Cetylated Fatty Acids
2022 was the year of Lipocet®, the innovative cetylated fatty acid-based novel food developed and patented by PharmaNutra. The classification of CFAs as Novel Foods represents a fundamental strategic asset for the Group, which therefore focuses on the research, development and marketing of new oral solutions for musculo-skeletal well-being. September 2022 saw the market launch of Cetilar® Oro, the first food supplement in oral suspension based on cetylated esters (CFA).

In 2020 the Cetilar® products obtained Play Sure Doping Free certification from the No Doping Life association, in technical partnership with Bureau Veritas Italia. The Play Sure Doping Free seal certifies the products as free of any substance considered potentially doping and are therefore particularly suited to sports people of any level.
In the heart of the territory

“InPharmaNutra is the combination of R&D activities of the highest level, with a strong commercial attitude. This translates into great deployment, the ability to concretely implement an idea and obtain a tangible result.”

CINZIA CORASINITI
Commercial Director PharmaNutra S.p.A.

Innovation, scientific competence and the defence of intellectual property. These company values are also reflected in its sales structure. A business model created on the basis of the special features of the domestic market, but which has rapidly and effectively adapted to international needs.

The PharmaNutra Group works on the Italian market through its own network of over 180 ISCs (Pharmaceutical Representatives), who are the company’s real driving force in the country. A far-reaching and yet flexible network divided into four specific sales lines: Primary, Supportive, Junia Pharma and Nutrition.

AN APPROACH DRIVEN BY MARKET PERFORMANCE, BUT BASED ON...

◆ Flexibility and reactivity
These characteristics have led to the integration of remote information and sales tools, thus developing a new sales system able to capture the changing needs of the market. Using high-tech information tools, the network is able to exploit the synergies created by the physical distribution activities and the tools for online activities, to meet the needs of doctors and pharmacies rapidly, efficiently and without barriers.

◆ Continuous training
Professional growth is guaranteed by a system of continuous training of professional figures, monitoring their performance and scientific knowledge. The ISC figure is central to the dissemination of medical information and the product distribution system, and their professionalism in the field is one of the company’s founding values. Further supporting the activities in the territory, the in-house Customer Care department monitors the developments of the national market to strengthen and support the sales network. This organisational model has led to the development of one of the key factors of success of PharmaNutra products: increasing doctors’ loyalty and directly managing the pharmacies and the distribution network.

◆ Competitive Time-to-Market
It can only be guaranteed through rigorous scientific research, high quality standards and innovative proprietary technologies. These factors have allowed the PharmaNutra Group to launch 12 new products on the Italian market in the last three years, consolidating its leadership in the iron-based therapy market and strengthening its presence in the mineral-based nutritional supplements sector, as well as that of medical devices for joint and muscle recovery.

PRODUCT PORTFOLIO EVOLUTION

REGISTERED TRADEMARKS
PharmaNutra is present on foreign markets with a flexible and innovative business model, based on a consolidated network of top-class partners. Synergies in individual countries are sought using specific criteria, aiming to select growing yet well-structured companies that base their own business on innovative, high-quality products, sound scientific research and a sales structure that is as close as possible to the values of PharmaNutra. The company began developing foreign markets in 2013 and recorded constant growth right from the start. Currently, the Group’s products are distributed in 67 countries in Europe, Asia, Africa and America, through a network of 45 carefully selected sales partners.

As part of new international growth strategies, PharmaNutra USA and PharmaNutra España were established, wholly owned subsidiaries of PharmaNutra SpA. The American market is a key market for foreign development, an important strategic choice that was initiated with determination a few years ago by obtaining patents for products in the Cetilar® line and registering the SiderAL® and Cetilar® trademarks. During the course of 2023, PharmaNutra USA will begin marketing PharmaNutra-branded nutritional supplements and medical devices (which will be classified as cosmetics), both through on-line e-commerce channels and through direct distribution in the territory. The Spanish market, due to its similarities to the Italian market, requires a physical presence in the territory. Since spring 2023, the marketing of the Cetilar® and Cetilar® Nutrition line of products has started via the e-commerce channel and through a dedicated network for direct sales in the territory.

“PharmaNutra continues its internationalisation programme; every day our partners help us to exploit the huge potential for development on foreign markets”.

CARLO VOLPI
Chief Operating Officer, PharmaNutra S.p.A.

OUR NEXT GOALS

- Consolidation of sales growth with existing partners
- Cross-selling and expansion of the product portfolio in countries with consolidated partners
- Launch of sales activities in the countries where agreements were signed in the last year
- Development of foreign subsidiaries in the American and Spanish markets
- Strengthening of cross-border e-commerce strategies in China
Cetilar® Nutrition was created to support sports performance and promote the intake of essential nutrients, providing athletes with a reliable source of energy during physical activity. Using the same scientific method, PharmaNutra’s R&D laboratories developed Cetilar® Nutrition products; an innovative line designed as a supplement for competitive athletes and for those who practise sport constantly, allowing them to perform while improving performance.

SIDERAL® LINE
Nutritional supplement containing Sucrosomial® Iron (Sideral® r.m) and vitamins, aimed at treating dietary deficiencies or when higher organic levels of these nutrients are required. Sucrosomial® Iron contained in SiderAL® products reduce the side-effects commonly associated with other types of iron, ensuring better absorption, high tolerability and efficacy.

SIDERAL® PRODUCTS ACCOUNT FOR 73.5% OF TURNOVER

SIDERAL® INTERNATIONAL LINE

CETILAR® LINE
Medical devices containing Cetylated Esters (CFA) for joint and motor recovery in osteoarthritic joint conditions. Cetilar® products are suited for treating contusions, strains, distortions, contractures and joint traumas generally.

CETILAR® PRODUCTS ACCOUNT FOR 10% OF TURNOVER

CETILAR® NUTRITION LINE
Cetilar® Nutrition was created to support sports performance and promote the intake of essential nutrients, providing athletes with a reliable source of energy during physical activity. Using the same scientific method, PharmaNutra’s R&D laboratories developed Cetilar® Nutrition products; an innovative line designed as a supplement for competitive athletes and for those who practise sport constantly, allowing them to perform while improving performance.

SIDERAL® PRODUCTS ACCOUNT FOR 73.5% OF TURNOVER

SIDERAL® INTERNATIONAL LINE

CETILAR® LINE
Medical devices containing Cetylated Esters (CFA) for joint and motor recovery in osteoarthritic joint conditions. Cetilar® products are suited for treating contusions, strains, distortions, contractures and joint traumas generally.

CETILAR® PRODUCTS ACCOUNT FOR 10% OF TURNOVER

CETILAR® NUTRITION LINE
Cetilar® Nutrition was created to support sports performance and promote the intake of essential nutrients, providing athletes with a reliable source of energy during physical activity. Using the same scientific method, PharmaNutra’s R&D laboratories developed Cetilar® Nutrition products; an innovative line designed as a supplement for competitive athletes and for those who practise sport constantly, allowing them to perform while improving performance.
SUCROSOMIAL® MINERALS
Nutritional supplements containing Sucrosomial® minerals, vitamins and amino acids, designed for everyday well-being and as a support for the immune defences.

Dietary supplement containing 19 micronutrients

Dietary supplement containing algal Calcium, Vitamin K2 and Vitamin D3, which aid the physiological functions of the bone tissue.

Nutritional supplement specifically formulated for pregnant women, containing Sucrosomial® Iron, folic acid, vegetable DHA, 9 vitamins and 8 microelements, all in one capsule.

APPOROTAL® ACCOUNTS FOR 10.8% OF TURNOVER

OTHER PROPRIETARY PRODUCTS
Nutritional supplement developed and marketed by PharmaNutra, aimed at treating dietary deficiencies or when higher organic levels of these nutrients are required, or simply to ensure everyday health and well-being.

BoneCal
Nutritional supplement containing algal Calcium, Vitamin K2 and Vitamin D3, which aid the physiological functions of the bone tissue.

DiKappa 2
Nutritional supplement containing Vitamin K2 and Vitamin D3, promoting intestinal calcium absorption and fixation in the bone tissue.

Novomega
Nutritional supplement containing EPA and DHA, used to integrate levels of nutrients to prevent cardiovascular disease.

Gestalys DHA
Nutritional supplement specifically formulated for pregnant women, containing Sucrosomial® Iron, folic acid, vegetable DHA, 9 vitamins and 8 microelements, all in one capsule.
branded products

SIDERAL® LINE
Nutritional supplement containing Sucrosomial® Iron and specific vitamins for the paediatric sector (0 – 16 years).

SIDERAL® INTERNATIONAL LINE

LACTOZEPAM® LINE
Nutritional supplement containing Lactium® (hydrolysed milk proteins) and Vitamin E, designed as a natural response to anxiety and sleep disorders.

OTHER PROPRIETARY PRODUCTS
OTC and nutritional supplements developed and marketed by Junia Pharma, aimed at treating dietary deficiencies or when higher organic levels of these nutrients are required, or simply to ensure everyday health and well-being.

PREScription Medicines
Ribomicin 0.3% is an ophthalmic broad-spectrum antibiotic containing Gentamicin, available in three formulations: eye drops, single dose solution and ointment.

produkts Under exclusive license
Infant formula made from whole goat’s milk, for infants from 0 to 18 months. Produced by Dairy Goat Co-operative and distributed in Italy by Junia Pharma.

BUSINESS MODEL

APPORTAL® Vital
Nutritional supplement with vitamins, Sucrosomial® minerals, amino acids, Royal jelly and coenzyme Q10, that help ensure and support three important biological functions: immunomodulating, restorative and energising.

DOLOMIR® Line
Medical devices containing myrrh extract, to protect the ear canal and the oropharyngeal mucosa.
PROPRIETARY RAW MATERIALS (ACTIVE INGREDIENTS)
Sucrosomial® macronutrients, micronutrients and phytoextracts. The innovative phospholipid membrane patented by Alesco and PharmaNutra allows elements to cross the gastric environment without reacting with the mucosa and other nutrients, to be absorbed directly in the blood flow.

OTHER TECHNOLOGIES
Vegetable glucosamine for healthy joint cartilage.
Complex of cetylated fatty acids (CFAs) developed to restore joint liquidity, ensuring normal flexibility and mobility of joints, muscles and tendons.

RAW MATERIALS UNDER EXCLUSIVE LICENSE IN ITALY
Active ingredients and raw materials marketed by Alesco for the pharmaceutical, nutraceutical and food industry.
Non-invasive Diagnostic instruments and medical software for monitoring body composition using bioimpedance techniques.

**DIAGNOSTIC INSTRUMENTS**

*NUTRI LAB™*  
*BIA101 PRO*  
*BIA101 MED*

**MEDICAL SOFTWARE**

*HBO HOSPITAL BODYGRAM*  
*BODYGRAM DASHBOARD*
YEARS ANNIVERSARY

COMMITMENT
Our commitment, our passions

“Sport is in our DNA. Determination, entertainment as well as education and respect. These are the values that sport teaches us and are those on which life in the company is based, every day”.

ANDREA E ROBERTO LACORTE
Founders of PharmaNutra S.p.A.

THE COMMITMENT TO SPORT, TO CONCRETELY AND TANGIBLY SHARE THE PRINCIPLES DRIVING THE COMPANY

The bond between PharmaNutra and the sports world is inseparable. Two worlds, driven by the same principles: determination, passion, growth, but also team playing, inclusion and, above all, goals. Through its constant support for sporting activities and events, PharmaNutra aims to promote sociality, the territory and attention to the environment, as well as a healthy, active lifestyle.
Sports sponsorship

Main Sponsor: Pre-match & Medical Partner: Official Supplier:

Medical Partnerships

CETILAR ACADEMY PROJECT

Cetilar Academy è un nuovo progetto grazie al quale PharmaNutra supporta la crescita atletica, professionale e umana di futuri talenti dello sport impegnati in società dilettantistiche di eccellenza, tra cui le promesse del motorsport della scuderia Kart Republic e i giovani calciatori della società parmense U.S. Arsenal.

EVENTS SPONSORED BY THE PHARMANUTRA GROUP

"Human Performance" comes from the partnership between the Cetilar® brand and the Luna Rossa Prada Pirelli Team. This training path was designed to improve the physical and mental performance of the Luna Rossa crew, supported by a top-level scientific team that, with the support of Cetilar®, will monitor the crew’s athletic training up to the America’s Cup 2024 in Barcelona.

Obiettivo3 is a project promoted by champion Alex Zanardi to recruit, launch and concretely and economically support disabled persons wishing to take up a sport. Since 2019, PharmaNutra, through the brand Cetilar®, has been supporting Obiettivo3 athletes, through the purchase of new handbikes and funding for participation in sports events.
Support to research and scientific dissemination

“Scientific partnerships with universities and research institutes have been fundamental for the growth of the company. Without them, we would not be here, and this is why we are committed to return value to the healthcare and science world.”

ANDREA LACORTE
President and co-founder, PharmaNutra S.p.A.

MAKING A DIFFERENCE IN THE HEALTH AND INNOVATION WORLD MEANS:

SHARING SCIENTIFIC KNOWLEDGE AND VALUES
Right from its establishment, the Group has always invested in research and scientific dissemination projects. With the involvement of doctors, specialists and researchers in international conferences, PharmaNutra is committed to raising awareness and updating the scientific world on the issue of iron deficiency and related diseases. In addition to this commitment, we also support the organisation of many CME courses reserved for the medical profession.

BELIEVING IN THE FUTURE AND IN OUR TALENTS
Training is one of the key pillars for the future: PharmaNutra is working to launch a professional academy project, in partnership with Italian universities, to recruit young talents in the company. Furthermore, the private cellular biology and pharmaceutical technique laboratories at the new headquarters will be at the disposal of the partner universities for new medical and pharmacological studies and research.